IGFBP-1 (placenta protein pp12) ELISA


Insulin-like growth factor binding protein-1, placenta protein 12, pp 12, BP-25, a1-pregnancy associated endometrial globulin, alpha1-PEG or a1-PEG, somatomedins-binding protein


  EU registration number

Order Code No.:

Shelf Life:
9 months after date of manufacture

Importance in the clinical routine for: Gynecologists (Early diagnosis of possible pregnancy risks); Pediatricians

This ready-to-use in-vitro test kit is designed to quantitatively determine the level of IGFBP-1 in human serum in order to diagnose risk pregnancies as well as to prognosticate fetal and postnatal development. Increased concentrations of IGFBP-1 impair both placental growth and fetal growth and may damage the fetus or lead to a miscarriage.


Increased IGFBP-1 concentrations are already detectable 3 to 6 weeks in advance of clinical symptoms such as fetal hypotrophy or hypoxia, pre-eclampsia or intrauterine death of the fetus. Detection of IGFBP-1 levels therefore allows an early beginning of adequate therapies.


Further indications for application of the test

  • Diabetes mellitus
  • Twin pregnancies
  • Functional evaluation of the endometrium


To order the IGFBP-1 ELISA please refer to the BIOSERV catalogue number BS-30-10.

Principle of the test

Solid phase enzyme immunoassay for the quantitative determination of IGFBP-1 concentrations. The BIOSERV Diagnostics IGFBP-1 ELISA is based on the sandwich principle using monoclonal antibodies.


Sample material:

  • serum

More details on IGFBP-1

The Insulin-like growth factor binding protein-1 (IGFBP-1) is an acid-stable protein. It is no placental protein in the true sense, but is secreted by the endometrium or the decidua, respectively.


IGFBP-1 inhibits both placental and fetal growth by minimizing the amount of IGF molecules available in the maternal organism. By binding and neutralizing free IGF, unlimited proliferation of the trophoblast into the decidual endometrium is prevented. High IGFBP-1 concentrations may lead to retardation, at the worst to the intrauterine death of the fetus and to miscarriage.


The IGFBP-1 concentration may influence the IGF concentration in serum such that in case of insulin deficiency (Diabetes mellitus type I) serum concentration of IGFBP-1 will be increased while decreased levels occur if insulin is overproduced (Insulinom).


Analysis of IGFBP-1 in amniotic fluid is considered to be the best marker for detecting fetal growth disorders. Concentrations of IGFBP-1 in the amniotic fluid are 100 to 500 times increased compared to maternal or fetal serum. By determining the titer of IGFBP-1, retardations of the fetus can be detected much earlier than by using ultrasonography. The highest concentrations of IGFBP-1 in amniotic fluid are reached in the 2nd trimester and between the 24th and 25th week of pregnancy. Elevated concentrations of IGFBP-1 show up either as relatively small peaks or over a longer period of time. In both cases complications are to be expected though, e.g., pathohistological alterations of the placenta. Repeated examinations to monitor high risk pregnancies, primarily between the 24th and 35th week of pregnancy, are strongly recommended.


Women with twin pregnancies reveal significantly higher IGFBP-1 levels, especially within the 10th to 20th week, compared to single pregnancies. Since multiple pregnancies do not show higher values than twin pregnancies, the maximum secretory capacity of the endometrium seems to be obtained in twin pregnancies.


During the stimulation phase, increased levels of IGFBP-1 combined with IGF-1 concentrations are essential in order to evaluate the corpus luteum regulation. Women found to have a polycystic ovary syndrome reveal normal IGF-1 levels and increased levels of luteinizing hormone and increased levels of insulin while the concentration of IGFBP-1 is reduced.


Furthermore, IGFBP-1 is an important indicator for recognizing ruptures of the fetal membrane. In those cases, IGFBP-1 levels of vaginal secretion are drastically increased up to 200-fold. Detection of IGFBP-1 therefore ensures a reliable diagnosis of fetal membrane ruptures with a very high diagnostic specificity.


Trisomy 18 (Edward syndrome) is also indicated by elevated IGFBP-1 values in combination with a low concentration of IGF-BP2 during the 1st trimester. In the serum of non-pregnant women as well as men IGFBP-1 is present only in traces, approximately 20 ng/ml. Continuous evaluations of IGFBP-1 throughout the day revealed strong alterations of protein binding values in dependency of the time of day and food intake. In conclusion patients’ samples should always be taken at a fixed time, preferably in the morning.



For further inquiries please contact us: info@bioserv-diagnostics.com